Recent Quotes (30 days)

You have no recent quotes
chg | %

Wex Pharmaceuticals Inc.  

(Public, TSE:WXI)   Watch this stock  
Find more results for WXI
Apr 9 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range     -
52 week 0.12 - 0.35
Open     -
Vol / Avg. 0.00/2,000.00
Mkt cap 68.58M
P/E     -
Div/yield     -
EPS -0.12
Shares     -
Beta 1.15
Inst. own     -

Key stats and ratios

Q4 (Dec '10) 2010
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -27.96% -38.84%
Return on average equity -29.90% -43.54%
CDP Score - -


Suite 1601 700 West Pender Street
+1-604-6838880 (Phone)
+1-604-6838868 (Fax)

Website links


WEX Pharmaceuticals Inc. is engaged in the discovery, development, manufacture and commercialization of drug products treat pain management. The Company�s platform is tetrodotoxin (TTX), a selective sodium channel blocker. Its product based on TTX is in Phase III clinical development for the treatment of cancer-related pain. As of December 31, 2010, it has completed five clinical trials with TTX, with more than 200 patients treated. The Company products include TTX for cancer-related pain, TTX for chemotherapy-induced neuropathic pain and Scientific Publications. The Company�s TEC-006 is a clinical trial for the treatment of moderate to severe inadequately controlled cancer-related pain. Its TTX-CINP-201 is a clinical trial for the treatment of moderate to severe neuropathic pain caused by chemotherapy in patients with cancer. The Company is a subsidiary of CK Life Sciences Int�l., (Holdings) Inc. (CKLS).